Lawrence T. Kennedy Jr - 03 Jan 2023 Form 4 Insider Report for BIODESIX INC (BDSX)

Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Lawrence T. Kennedy, Jr.
Issuer symbol
BDSX
Transactions as of
03 Jan 2023
Transactions value $
$0
Form type
4
Filing time
05 Jan 2023, 20:20:44 UTC
Previous filing
05 Jan 2023
Next filing
25 May 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Restricted Stock Units Award $0 +91.5K $0.00 91.5K 03 Jan 2023 Common Stock 91.5K Direct F1, F2, F4
transaction BDSX Restricted Stock Units Award $0 +27.4K $0.00 27.4K 03 Jan 2023 Common Stock 27.4K Direct F1, F3, F4
transaction BDSX Stock Options (Right to Buy) Award $0 +125K $0.00 125K 03 Jan 2023 Common Stock 125K $2.05 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer common stock.
F2 These RSUs will vest in full on January 3, 2024, generally subject to the Reporting Person's continued service on the Issuer's board of directors (the "Board") through the applicable vesting date, and have no expiration date.
F3 These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service on the Board through the applicable vesting date, and have no expiration date.
F4 Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer.
F5 This option vests 40% on January 3, 2025, and the remaining 60% in 36 successive, equal monthly installments measured from January 3, 2025, generally subject to the Reporting Person's continued service on the Board through the applicable vesting date.